On February 5, 2025 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, reported the closing of its previously announced best-efforts public offering of 762,500 common shares at a public offering price of $4.00 per share (Press release, BriaCell Therapeutics, FEB 5, 2025, View Source [SID1234650080]). The Company received gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, of $3.05 million. The Company relied upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives.

ThinkEquity acted as sole placement agent for the offering.

The securities were offered and sold pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-276650), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on January 22, 2024 and declared effective on January 31, 2024. The offering was made by means of a prospectus supplement and prospectus which have been filed with the SEC and are available on the SEC’s website at www.sec.gov . You should read the applicable prospectus supplement and prospectus for more complete information about the Company and the offering. You may obtain these documents free of charge by visiting the SEC website at www.sec.gov . Alternatively, you may obtain copies by contacting ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On February 4, 2025 Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, reported that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is being held virtually (Press release, Corvus Pharmaceuticals, FEB 4, 2025, View Source [SID1234650025]). The presentation will be on Tuesday, February 11, 2025 at 9:20 am ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.

On February 4, 2025 Akribion Therapeutics ("Akribion"), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, reported its exit from stealth and the completion of a Seed Financing round raising EUR 8 million to accelerate the development of novel therapeutics based on Akribion’s proprietary G-dase E nucleases (Press release, , FEB 4, 2025, View Source [SID1234650042]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The round was led by CARMA FUND and RV Invest, with investments from MP Beteiligungs GmbH, Hessen Kapital I, Bruker Invest and High-Tech Gründerfonds.

Lukas Linnig, Co-Founder and Co-CEO of Akribion said, "Akribion is unlocking a whole new class of therapeutic possibilities with our approach. Our proprietary G-dase E nucleases allow very specific depletion of certain subsets of cells based on the presence of a predetermined RNA sequence. While we are initially focused on advancing groundbreaking precision oncology therapies, we believe that this approach to programmable cell depletion could have much wider application. I would like to thank our investors for their commitment to Akribion and for their support in helping us realize the potential of our technology."

Dr. Martin Raditsch, General Partner, CARMA FUND, commented: "Akribion’s unique technology enables the creation of a new class of oncology therapeutics. We are looking forward to working alongside this enthusiastic team to develop new cancer treatments with improved outcomes for patients in this prevalent and hard to treat indication."

Dr. Aleksei Zeifman, Investment Director, RV Invest, commented: "We’re thrilled to support Akribion’s entrepreneurial team as they seek to unlock the full potential of their unique technology. The high adaptability of the G-Dase E platform makes it a perfect tool to leverage our emerging knowledge of the genomic signatures of diseases across various therapeutic areas."

Akribion is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Armed with a G-dase E payload, it has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence. This ensures that only the targeted cells are affected, leaving healthy cells unharmed.

The G-dase E technology was discovered by Dr. Paul Scholz and his team at BRAIN Biotech AG, the specialist in biosolutions for industrial applications, during Michael and Lukas’s tenure there. Dr. Scholz has also joined Akribion as Head of Research and Development.

Initially targeting HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC), Akribion is exploring applications in additional oncology indications, as well as in autoimmune diseases, fibrosis, infectious diseases, and more. The flexibility and broad potential of Akribion’s technology makes it a promising platform for various therapeutic areas, as by simply changing the guide RNA, the technology can be quickly adapted to target different cells, making it much faster to develop new treatments compared to traditional methods.

The current financing round is expected to deliver in vivo Proof of Concept of Akribion’s technology.

Akribion is led by Dr. Michael Krohn and Lukas Linnig, Co-Founders and Co-CEO’s. Dr. Adel Nada has also been appointed as board Chair to support the management team. Adel is a biotech executive and multi-time founder and operator. He is currently a venture partner with Volnay Therapeutics, a cell and gene therapy investor and incubator based in the US. The experienced Board of Directors also includes Dr. Martin Raditsch, CARMA FUND, Dr. Aleksei Zeifman, RV Invest, and Dr. Katharina Severin, High-Tech Gründerfonds. The management team includes Dr. Paul Scholz, Head of Research and Development, Dr. Dirk Sombroek, Head of Strategic Partnerships, and Dr. Oliver Grünvogel, Head of Strategy and Operations.

On February 4, 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, reported that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Lifesciences Conference on February 11, 2025 at 12:40pm ET. The conference is being held virtually February 11-12, 2025 (Press release, Lineage Cell Therapeutics, FEB 4, 2025, View Source [SID1234650026]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can view a replay of the presentation on the Events and Presentations section of Lineage’s website. Additional videos are available on the Media page of the Lineage website.

On February 4, 2025 Merck reported Fourth-Quarter 2024 Financial Results (Presentation, Merck & Co, FEB 4, 2025, View Source [SID1234650043]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!